Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) shares saw unusually-high trading volume on Wednesday . Approximately 13,673,293 shares traded hands during trading, an increase of 504% from the previous session’s volume of 2,264,315 shares.The stock last traded at $6.22 and had previously closed at $4.94.

PGNX has been the topic of a number of recent research reports. Brean Capital reiterated a “buy” rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a report on Friday, May 6th. Jefferies Group restated a “buy” rating on shares of Progenics Pharmaceuticals in a report on Friday, June 10th. Zacks Investment Research lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Progenics Pharmaceuticals in a report on Monday, April 4th. Finally, BTIG Research restated a “buy” rating and issued a $9.00 target price on shares of Progenics Pharmaceuticals in a report on Wednesday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Progenics Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $10.35.

The firm’s 50-day moving average is $4.83 and its 200 day moving average is $4.69. The company’s market cap is $429.47 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.05. During the same period in the prior year, the company posted ($0.15) EPS. The business had revenue of $2.50 million for the quarter, compared to analyst estimates of $3.27 million. The business’s quarterly revenue was up 908.1% compared to the same quarter last year. Equities research analysts forecast that Progenics Pharmaceuticals Inc. will post $0.12 EPS for the current fiscal year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.